Would they really want to appeal?
Surely it would require evidence that PBs are efficatious at treating GD enough to warrant the risks? At the moment we only have evidence of short term effectiveness (not efficacy and not long term) and the evidence on risk is poor.
That's not the kind of thing you can magic up overnight. It would seem mad to squander money on a quixotic appeal when the review conclusions can be amended if evidence appears in future.